(Re-correction) "Reference Data for FY2025 Consolidated Financial Results"
Filed with TSE · · 64 pages · English
Watch Daiichi Sankyo's latest callDaiichi Sankyo (Tokyo:4568) Q1 2026 Earnings Call · Replay · Jul 31Read the transcript of Daiichi Sankyo (Tokyo:4568) Q1 2026 Earnings CallCompany name: DAIICHI SANKYO COMPANY, LIMITED Representative: Hiroyuki Okuzawa, Representative Director, President and CEO (Code no.: 4568, Prime Market, Tokyo Stock Exchange) Please address inquiries to Ari Fujishiro, Corporate Officer, Head of Investor Relations and Shareholder Relations Department Telephone: for media +81-3-6225-1126 for stock market participants +81-3-6225-1125 (Re-correction)
Daiichi Sankyo Company, Limited on 6ix
Story so far
- (Correction) Partial Correction of "Financial Results for the Fiscal Year Ended March 31, 2026 [IFRS] (Consolidated)"
- Daiichi Sankyo: Consolidated Financial Statements and Independent Auditor's Report for FY2025PDF
- Daiichi Sankyo Announces Occurrence of Losses Related to Review of Product Supply Plans and Revision of Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026
Earlier from Daiichi Sankyo
- (Correction) Partial Correction of "Financial Results for the Fiscal Year Ended March 31, 2026 [IFRS] (Consolidated)"
- Enhertu(R) Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Own Shares as Restricted Share-Based Compensation
- Daiichi Sankyo Announces Disposal of Own Shares as Medium-Term Performance-Based Share Compensation for Company’s Directors and Corporate Officers
- Daiichi Sankyo - Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Later from Daiichi Sankyo
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
- Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Follow Daiichi Sankyo into a list and get an email when it puts out news.
Follow Daiichi Sankyo